212 related articles for article (PubMed ID: 36648736)
1. Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies.
Harris L; O'Connell T; Woolley JJ; L'Italien G; Martin T; Coric V; Moren JA
Adv Ther; 2023 Mar; 40(3):1141-1152. PubMed ID: 36648736
[TBL] [Abstract][Full Text] [Related]
2. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
4. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
5. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
8. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
[TBL] [Abstract][Full Text] [Related]
9. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
11. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
13. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
Raffaelli B; Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Reuter U
J Headache Pain; 2022 Mar; 23(1):40. PubMed ID: 35350990
[TBL] [Abstract][Full Text] [Related]
14. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
15. Trends in utilization and costs of migraine medications, 2017-2020.
Nguyen JL; Munshi K; Peasah SK; Swart ECS; Kohli M; Henderson R; Good CB
J Headache Pain; 2022 Aug; 23(1):111. PubMed ID: 36031609
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
18. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for the prevention of migraine.
Raffaelli B; Neeb L; Reuter U
Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
[No Abstract] [Full Text] [Related]
20. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population.
Lazaro-Hernandez C; Caronna E; Rosell-Mirmi J; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
J Headache Pain; 2024 Feb; 25(1):21. PubMed ID: 38347485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
